Business Wire

SEOUL-VIOSYS

2.9.2022 11:56:41 CEST | Business Wire | Press release

Share
Seoul Viosys to Demonstrate the Unparalleled Value of Its Micro-LED at IFA 2022

Seoul Viosys (“SVC”) (KOSDAQ: 092190), a manufacturer of optical semiconductor devices, will present micro-LED based on the laminated structure – which enables high-resolution display – as well as its micro-LED display products at the IFA (Internationale Funkausstellung Berlin) 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220902005087/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Remarkable color mixing technique developed based on Seoul Viosys’s unique technology (Graphic: Business Wire)

The stacked micro-LED developed by Seoul Viosys has a unique and innovative structure in which three chips representing red, green, and blue (R/G/B) are vertically arrayed instead of the usual horizontal array. Its main difference from conventional micro-LEDs is that its R/G/B LED in the stacked structure emit colors as if they constitute a single pixel through perfect color mixing.

Micro-LED produced by Seoul Viosys can achieve deep black color and clear image thanks to the stacked structure. Also, as colors combining R/G/B are emitted externally from inside a pixel, viewers can enjoy clear pictures without distortions from any direction.

The stacked micro-LED to be presented by Seoul Viosys at the exhibition is based on an innovative future technology that can manufacture 4K display screens between 100 and 200 inches. There will be a space where visitors can experience micro-LED in the company’s booth. It will show two micro-LED displays, including a 54-inch high-resolution 0.625mm pitch (P0.625) display and an 81.5-inch 0.9375mm pitch (P0.9375) display. Visitors will be able to enjoy highly immersive clear pictures wherein each pixel comes alive.

Various products representing key production processes of Seoul Viosys’s micro-LED, which have not been unveiled publicly, will also be on display. By exhibiting epitaxial wafers, cabinets, and other products fabricated using high-level transfer technology of moving micro-LED to a display substrate, the company will offer differentiated prices and quality while demonstrating its distinctive values.

In addition, Seoul Viosys will have an exhibition on its display LED techniques supporting its micro-LED technology, such as the molding technique that controls the moiré phenomenon and highlights the details of the black color, the low reflection technique that helps achieve vivid colors and high contrast ratios in the light, and the customized free form-factor design cabinet display that allows easy installation and replacement of microdisplay and change to various sizes.

As micro-LED has to run stably on extremely low power, it is difficult to achieve technological innovation without LED growth technology. Seoul Viosys already owns quantum efficiency enhancement technology for 1㎛-sized micro-LED through joint research with Nobel Laureate Shuji Nakamura, a professor at UC Santa Barbara, the U.S. The company also operates entire processes from the production of a red-green-blue light-emitting substrate to the manufacturing of devices and modules. Notably, WICOP, Seoul Viosys’s original technology, was applied to its micro-LED. WICOP is a key source technology that is necessary for producing micro-LED. It enables the fabrication of micro-scale chips by using no additional parts such as wires and has high reliability due to process simplification.

“By securing WICOP, a source technology for micro-LED and mini-LED, and quantum efficiency enhancement technology, Seoul Viosys is now ready to address any customer requests,” President Hwang Jeong-hwan of Seoul Viosys said. “Our micro-LED will enable the best image quality that viewers have never experienced before, and offer the top-notch solution in the rapidly changing large display market.”

He continued to say, “Seoul Viosys is introducing its products integrated for the purpose of providing a better solution to our customers, comprising LED, molding, and cabinet technologies, and demonstrating its competence,” once again stressing the company’s management principle of ‘no competition with customers.’

Seoul Viosys will introduce its Real One Pixel product that will be presented at the IFA 2022 on its social channels including YouTube (https://www.youtube.com/watch?v=kMJUzwxDqxk).

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Real One Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2019). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Real One Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220902005087/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye